Rhumbline Advisers Lowers Position in Quanterix Co. (NASDAQ:QTRX)

Rhumbline Advisers trimmed its position in shares of Quanterix Co. (NASDAQ:QTRX) by 5.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,480 shares of the company’s stock after selling 3,224 shares during the quarter. Rhumbline Advisers owned approximately 0.15% of Quanterix worth $600,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in QTRX. Portolan Capital Management LLC increased its holdings in Quanterix by 31.4% in the third quarter. Portolan Capital Management LLC now owns 2,520,686 shares of the company’s stock valued at $32,668,000 after buying an additional 602,656 shares in the last quarter. Easterly Investment Partners LLC grew its position in shares of Quanterix by 26.5% during the 3rd quarter. Easterly Investment Partners LLC now owns 876,133 shares of the company’s stock valued at $11,355,000 after acquiring an additional 183,387 shares during the period. Pier Capital LLC increased its stake in shares of Quanterix by 23.5% in the 3rd quarter. Pier Capital LLC now owns 511,798 shares of the company’s stock valued at $6,633,000 after purchasing an additional 97,256 shares in the last quarter. Graypoint LLC acquired a new position in Quanterix in the 4th quarter worth about $691,000. Finally, Algert Global LLC boosted its position in Quanterix by 75.9% during the third quarter. Algert Global LLC now owns 137,833 shares of the company’s stock worth $1,786,000 after purchasing an additional 59,496 shares in the last quarter. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Quanterix Stock Down 1.2 %

QTRX stock opened at $7.40 on Friday. Quanterix Co. has a 52 week low of $6.80 and a 52 week high of $29.70. The firm has a 50-day simple moving average of $9.04 and a 200-day simple moving average of $11.29. The stock has a market capitalization of $285.08 million, a P/E ratio of -6.98 and a beta of 1.33.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Monday, December 23rd. The company reported ($0.22) earnings per share (EPS) for the quarter. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, analysts expect that Quanterix Co. will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, TD Cowen boosted their price objective on Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research report on Wednesday, November 13th.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.